Alligator Bioscience announced the publication of the results from a clinical phase I first-in-human study of the CD40 agonistic antibody ADC-1013. The top line data from this study was presented at the Society for Immunotherapy of Cancer (SITC) in November 2017. The results show that the agonistic anti-CD40 antibody ADC-1013 is safe and tolerated at clinically relevant dose levels. Furthermore, the pharmacodynamic effects and the preclinical data support the further clinical development of ADC-1013 against cancer and demonstrate the potential of ADC-1013 as a combination therapy with PD-1 targeted therapies.